IP Law 360

JANUARY 14, 2022

Ranbaxy Inc. is urging a Boston federal judge to give it equal time to defend itself in an upcoming "bet-the-company" trial with tens of billions of dollars potentially at stake on claims it manipulated the drug approval process to block competitors from making generic versions of three drugs.

40

40

IP Law 360

APRIL 22, 2022

Ranbaxy Pharmaceuticals drug purchasers asked a Massachusetts federal court Friday to approve their proposed $485 million global settlement with the generic-drug maker and its parent company over antitrust claims, arguing that the agreement provides significant benefits for plaintiffs in the multidistrict litigation.

Settlement 52

Settlement Litigation 52

IP Law 360

NOVEMBER 23, 2021

Ranbaxy Pharmaceuticals Inc. didn't need to ever sell a dose of a drug to have wielded monopoly power over it, a Boston federal judge ruled Monday, rejecting the company's bid for an early win on antitrust claims in the multidistrict suit.

52

52

IP and Legal Filings

NOVEMBER 21, 2022

When the two or more companies discontinues and combines their assets as well as the liabilities into the another company that has been newly formed, that is when a merger is truly said to have been taken place in the legal sense. In this two or more companies basically join together to form an another new business entity.

Business 52

Business Marketing Marketing Ownership 52